A new review finds that IL-17 signaling provides a mechanistic bridge between psoriasis and cardiometabolic risk, positioning a single inflammatory pathway as a common thread running from the skin lesion to the vascular system.

The review, reported by AJMC, synthesizes evidence that interleukin-17 — the cytokine targeted by biologics such as secukinumab, ixekizumab and brodalumab in moderate-to-severe plaque psoriasis — operates beyond the epidermis. The same signaling axis that drives keratinocyte hyperproliferation and the characteristic PASI-defining plaques also acts on vascular tissue, adipose tissue and metabolic organs.

Why does this matter for dermatology?

Cardiometabolic comorbidity in psoriasis is well documented. Patients with moderate-to-severe disease carry elevated rates of obesity, type 2 diabetes, dyslipidemia, hypertension and major adverse cardiovascular events compared with the general population. Historically, clinicians have managed that burden as a set of separate comorbid conditions.

This review reframes the relationship. By identifying IL-17 as a shared signaling mechanism, it suggests the skin and the vasculature are not merely co-affected organs in the same patient but targets of the same upstream driver. For dermatologists, that framing carries practical weight: the choice of systemic agent may have implications that extend past the skin.

What does the pathway actually do?

IL-17 sits at the center of the psoriasis inflammatory cascade. Released largely by Th17 cells, it promotes the chemokine and cytokine network that sustains cutaneous inflammation. But IL-17 receptors are expressed on non-skin tissues as well, and the review compiles evidence of the cytokine's activity in:

• vascular endothelium, with implications for atherosclerosis
• adipose tissue and lipid metabolism
• glucose homeostasis and insulin sensitivity

The result is a picture of psoriasis as a systemic inflammatory disease in which IL-17 signaling couples the visible dermatologic phenotype to long-term cardiometabolic risk.

What questions remain open?

The mechanistic link raises a therapeutic question the review cannot yet close definitively: does blocking IL-17 change cardiometabolic outcomes, not just skin scores? Randomized outcome trials with hard cardiovascular endpoints in psoriasis populations remain scarce, and observational data on biologic exposure and cardiovascular events have produced mixed signals.

Until those data mature, the review's contribution is conceptual but clinically concrete. It gives dermatologists a biologically grounded reason to treat comorbidity screening — lipid panels, glycated hemoglobin, blood pressure, body mass index — as integral to psoriasis management rather than an adjunct to it.

It also strengthens the case for early, effective control of systemic inflammation in moderate-to-severe disease. If IL-17 is the bridge, then suppressing it at the skin may matter for what happens on the other side.

Whether future trial designs will capture cardiometabolic endpoints alongside PASI responses remains the decisive question, and the review signals that the field is now asking it.